| 苗玉迪,胡星星,李艳春,李程亮,赵乔佳杰.血清IL-17、IL-32、IL-33、IL-37联合检测对初治多发性骨髓瘤患者早期治疗反应性的预测价值[J].,2022,(22):4279-4284 |
| 血清IL-17、IL-32、IL-33、IL-37联合检测对初治多发性骨髓瘤患者早期治疗反应性的预测价值 |
| Predictive Value of Combined Detection of Serum IL-17, IL-32, IL-33 and IL-37 in Early Treatment Response of Primary Multiple Myeloma Patients |
| 投稿时间：2022-05-07 修订日期：2022-05-31 |
| DOI：10.13241/j.cnki.pmb.2022.22.015 |
| 中文关键词: 多发性骨髓瘤 IL-17 IL-32 IL-33 IL-37 硼替佐米 治疗反应性 预测价值 |
| 英文关键词: Multiple myeloma IL-17 IL-32 IL-33 IL-37 Bortezomib Treatment response Predictive value |
| 基金项目:陕西省社会发展科技攻关项目（2015SF065） |
|
| 摘要点击次数: 989 |
| 全文下载次数: 444 |
| 中文摘要: |
| 摘要 目的：探讨血清白细胞介素-17（IL-17）、白细胞介素-32（IL-32）、白细胞介素-33（IL-33）、白细胞介素-37（IL-37）联合检测对接受硼替佐米为基础一线治疗方案的初治多发性骨髓瘤（MM）患者早期治疗反应性的预测价值。方法：选择2018年7月至2021年3月期间陕西省人民医院收治的初治MM患者176例为研究对象，所有患者均接受以硼替佐米为基础一线的治疗方案，根据早期治疗反应性分为敏感组（142例）和非敏感组（34例）；采用酶联免疫吸附法检测并比较两组血清IL-17、IL-32、IL-33、IL-37水平，并分析其联合检测对早期治疗反应性的预测价值。结果：敏感组治疗前血清IL-17、IL-32水平低于非敏感组，IL-33、IL-37水平高于非敏感组（P＜0.05）。多因素logistic回归分析显示，年龄≥65岁、血清IL-17≥29.70 pg/mL、IL-32≥63.02 ng/L、肿瘤分期III期是早期治疗反应性的危险因素（P＜0.05），IL-33＞141.97 pg/mL、IL-37＞69.17 ng/L是保护因素（P＜0.05）。血清IL-17、IL-32、IL-33、IL-37联合检测预测早期治疗反应性的曲线下面积（AUC）为0.866（95%CI：0.801~0.972）。结论：年龄、肿瘤分期、血清IL-17、IL-32、IL-33、IL-37是MM患者早期治疗反应性的影响因素，联合检测血清IL-17、IL-32、IL-33、IL-37水平对接受硼替佐米为基础一线治疗方案的初治MM患者早期治疗反应性预测价值较高。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the predictive value of the combined detection of serum interleukin-17 (IL-17), interleukin-32 (IL-32), interleukin-33 (IL-33) and interleukin-37 (IL-37) in the early treatment response of primary multiple myeloma (MM) patients who received bortezomib based first-line treatment. Methods: 176 cases of primary MM patients in our hospital from July 2018 to March 2021 were selected as the research object. All patients received bortezomib based first-line treatment. They were divided into sensitive group (142 cases) and non sensitive group (34 cases) according to the early treatment response. The levels of serum IL-17, IL-32, IL-33 and IL-37 in the two groups were detected and compared by enzyme-linked immunosorbent assay, and the predictive value of their combined detection for early treatment response was analyzed. Results: Before treatment, the levels of serum IL-17 and IL-32 in sensitive group were lower than those in non sensitive group, and the levels of IL-33 and IL-37 were higher than those in non sensitive group (P＜0.05). Multivariate Logistic regression analysis showed that age ≥ 65 years, serum IL-17 ≥ 29.70 pg/mL, IL-32 ≥ 63.02 ng/L, tumor stage III were the risk factors of early treatment response (P＜0.05), IL-33 > 141.97 pg/mL, IL-37 > 69.17 ng/L were the protective factors (P＜0.05). The area under the curve (AUC) of serum IL-17, IL-32, IL-33 and IL-37 combined detection in predicting early treatment response was 0.866 (95%CI: 0.801-0.972). Conclusion: Age, tumor stage, serum IL-17, IL-32, IL-33 and IL-37 are the influencing factors of early treatment response in MM patients. Combined detection of the levels of serum IL-17, IL-32, IL-33 and IL-37 has a high predictive value for early treatment response in MM patients receiving bortezomib based first-line treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
